The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States

Cancer

Volumn 120, Issue 12, 2014, Pages 1830-1837

  Nastoupil, Loretta J ^a   Sinha, Rajni ^b   Byrtek, Michelle ^c   Zhou, Xiaolei ^d   Taylor, Michael D ^c   Friedberg, Jonathan W ^e   Link, Brian K ^f   Cerhan, James R ^g   Dawson, Keith ^c   Flowers, Christopher R ^h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Pinnacle Health System   (United States)

^c GENENTECH INC   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g MAYO CLINIC   (United States)

^h EMORY UNIVERSITY   (United States)

Author keywords

follicular lymphoma; frontline therapy; non Hodgkin lymphoma; outcomes; rituximab maintenance

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

FOLLICULAR LYMPHOMA; FRONTLINE THERAPY; NON-HODGKIN LYMPHOMA; OUTCOMES; RITUXIMAB MAINTENANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, FOLLICULAR; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84902194519     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28659     Document Type: Article

References (19)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 3909-3918.
2. Cheson BD,. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2008; 6: 4-6.
3. Horning SJ,. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 20 (5 suppl 5): 75-88.
4. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009; 27: 1202-1208.
5. Nastoupil L, Sinha R, Byrtek M, et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (fl) used in the United States [abstract]. Blood. 2011; 118:Page 47. Abstract 97.
6. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995; 13: 140-147.
7. Hainsworth JD, Litchy S, Burris HA, 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002; 20: 4261-4267.
8. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108: 3295-3301.
9. Forstpointner R, Unterhalt M, Dreyling M, et al. German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006; 108: 4003-4008.
10. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood. 2004; 103: 4416-4423.
11. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377: 42-51.
12. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010; 28: 2853-2858.
13. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009; 27: 1607-1614.
14. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA,. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005; 23: 1088-1095.
15. Kahl B, Fangxin H, Williams ME, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing 2 different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]. Blood. 2011; 118:Page. Abstract LBA-6.
16. Casulo C, Maragulia J, Zelenetz AD,. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013; 13: 106-111.
17. Berger ML, Mamdani M, Atkins D, Johnson ML,. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health. 2009; 12: 1044-1052.
18. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML,. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health. 2009; 12: 1053-1061.
19. Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U,. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III. Value Health. 2009; 12: 1062-1073.